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Abstract   
Introduction: Studies of prognosis for surgery and corticosteroid injection for carpal tunnel 
syndrome have considered only a limited range of explanatory variables for outcome.  
 
Methods:  Data were prospectively collected on patient-reported symptoms, physical and 
psychological functioning, comorbidity and quality of life at baseline and 6 monthly for up to 2 
years. Outcomes were patient-rated change over a 6-month period and symptom-severity score at 
18 months. 
 
Results: 754 patients with CTS completed baseline questionnaires and 626 (83%) completed 
follow-up to 18 months.  Multivariable modelling identified, independent of symptom severity at 
outset, higher health utility, fewer comorbidities and lower anxiety as significant predictors of 
better outcome from surgery. In patients treated by steroid injection, independent of symptom 
severity at outset, shorter duration of symptoms and having no prior injection were significant 
predictors of better outcome.   
 
Discussion:  These multivariable models of outcome may inform shared decision-making about 
treatment for CTS. 
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Introduction  
Carpal tunnel syndrome (CTS) is the most common upper limb entrapment neuropathy, caused by 
compression of the median nerve at the wrist1. CTS can cause significant physical disability2 and is 
associated with anxiety, depression and reduced quality of life 3 4. Non-operative treatments such 
as immobilisation with a wrist brace and steroid injections, sometimes repeated 5, can provide 
effective short-term relief of symptoms6. Surgical release, however, is most effective for long-term 
symptom resolution 7, though it carries a greater risk of complications 8 9 and is possibly 
unnecessary for some 10 11. Further surgery is more costly than conservative measures. In the UK a 
total of 52,806 carpal tunnel releases or revisions were undertaken in 2011 costing £42 million12 
whilst in the USA 500,000 operations are performed annually for CTS at a cost of $2 Billion per 
year13.  
Some healthcare systems use restrictive policies where surgery is only offered in cases, where 
symptoms persist for more than three months after initial conservative therapy, or where the 
patient suffers from significant functional impairment or has neurological deficit 14.  Several 
studies have explored a range of prognostic factors for outcome from surgical and conservative 
treatments15-18. However, these studies were either limited by small sample sizes, a poor ratio of 
events to number of factors being studied resulting in overfitting, a restricted range of variables, 
the use of univariable analysis rather than multivariable models or were retrospective. There is a 
need for prospective studies to identify useful prognostic information in CTS which could be used 
to develop stratified care pathways,  better inform shared decision-making about individual 
treatment choices and guide treatment policies19. 
 
 
This article is protected by copyright. All rights reserved.
 
 
Prognostic research can be categorised into four types described by the PROGnosis RESearch 
Strategy (PROGRESS) partnership20 21, namely:  i) fundamental prognosis research (studies of the 
course of a condition in the context of current care) ii) prognostic factor research (studies to 
identify specific factors associated with prognosis); iii) prognostic model research (development 
and validation of a statistical model that can predict individual risk of a future outcome) and iv) 
stratified medicine (using prognostic information to tailor treatment to patients with particular 
characteristics and evaluation of its impact).     
The objective of our research was to identify which factors are associated with outcome from 
surgical release or steroid injection and therefore inform development of a prognostic model for 
further validation and testing. 
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Methods 
We conducted a multi-centre, prospective observational cohort study of patients diagnosed with 
CTS and managed according to best evidence (the ‘PalmS’ study). The study protocol has been 
published22.    
The study was approved by National Research Ethics Service Committee East of England – Norfolk 
(reference 13/EE/0106) and local Research Governance approval at each participating trust was 
obtained prior to recruitment.  All participants gave written informed consent prior to enrolment 
into the study. 
 
Derivation cohort 
Eligible patients were identified by a clinical neurophysiologist or hand surgeon whilst attending as 
out-patients at 5 secondary care sites in England between July 2013 and December 2015.  Patients 
were invited to participate if they fulfilled the following criteria: aged ≥18 years with newly 
diagnosed CTS in at least one hand confirmed by nerve conduction studies (NCS). Exclusion criteria 
were: carpal tunnel decompression in the affected (worst) hand in the last 12 months, pregnancy 
or up to 12 months post-partum, serious co-morbidities, other limb mono-neuropathies, sensory 
or motor disturbances secondary to stroke, multiple sclerosis or nerve injury, and inability to read 
and write English.  
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Candidate prognostic factors  
Putative prognostic factors of outcome from conservative or surgical treatment were identified 
through a literature search with consideration of what could be practically collected using patient 
report. Data were collected using a patient-completed report-form combining standardised 
validated and bespoke questionnaires.  They included: patient reported symptom severity using 
the  shortened Boston Carpal Tunnel Questionnaire (CTS-6)23, patient-reported hand function 
using the 3 subscales of the Michigan Hand Questionnaire24, psychological status using the 
Hospital Anxiety and Depression Scale25, health-related quality of life (EQ5D-3L)26 reported as 
utilities using UK-specific preference weights27, comorbidities using the Self-Assessed Comorbidity 
Questionnaire28. Baseline, 6, 12, 18 and 24 months follow-up questionnaires were completed by 
participants either online or by mail.  The following clinical and sociodemographic information was 
collected at baseline only: age, gender, ethnicity, duration of symptoms, height and weight, 
smoking status, weekly alcohol consumption in units (1 unit equivalent to 10ml pure alcohol), 
work status and type, and household income. Nerve conduction studies conducted at enrolment 
were obtained from participating centres and graded for electro-diagnostic severity according to 
Bland’s criteria29 to derive a baseline disease severity grade (grade 1 to 6).   
Patients recruited between July 2015 and December 2015 completed follow-up to 18 months only. 
All data collection was finalised by July 2017. 
 
Outcome measures 
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The primary outcome of interest was treatment success or failure defined with respect to the 
patient-reported global rating of change (GROC) for their worst hand only.  This was collected at 6 
monthly intervals by using a 5-point GROC for each hand (worse=1, unchanged=2, slightly 
better=3, much better=4, cured=5) compared to six months previously.  This scale was then 
dichotomised into a ‘success’ (a GROC of 3, 4 or 5) or a ‘failure’ (a GROC of 1 or 2).  Surgical 
outcome by GROC was also modelled using a more stringent dichotomisation by ‘much improved’ 
or ‘cured’ (GROC 4 and 5 only). When considering corticosteroid injections, an outcome was 
further considered a ‘failure’ if an individual later had surgery within the same 6 month period.   
A secondary outcome was symptom severity captured using the CTS-6 score23 at 18 months.   
With the exception of nerve conduction studies all other putative prognostic factors were patient-
reported as were the outcomes.  Treatments by injection or surgical release were also patient 
reported. For a randomly sampled subset of participants (10%) the General Practitioners were 
asked to complete a brief questionnaire about any steroid injection or surgery received for CTS 
and dates as captured in the patients’ primary care record. These were compared to the patients’ 
self-report to estimate the level of misreporting of treatments received. 
 
Statistical analysis  
All analyses were based on the hand with CTS. In those who had bilateral CTS the worst hand was 
selected and the corresponding subscales of the CTS-6, MHQ and GROC for that side.  The 
principal analysis was of treatment success or failure, i.e. the dichotomised GROC variable at the 
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follow-up time point immediately after treatment. A binary logistic regression model was used.  As 
data were collected in repeated 6-month time periods, each individual participant could have an 
intervention more than once during the total follow-up period. Therefore, Generalised Estimating 
Equations (GEEs) were used to account for the correlation between observations from different 
time periods within individuals.  It was intended to use an auto-regressive error structure, i.e. 
assuming the correlation to be weaker between ti me periods further apart than those closer 
together. However, due to the paucity of events this estimation was not possible and an 
independent error structure was used in the GEEs (which nonetheless would account for 
correlation between repeated observations within individuals when providing standard errors).  
Explanatory variables were the putative prognostic variables at baseline (when measured only 
once) or at the beginning of the 6 month period (where repeated measurements were made).  The 
association between explanatory and outcome (treatment success or failure) was expressed as an 
odds ratio (OR) with 95% confidence intervals.  
A second analysis was also made with the 18 month CTS-6 score as outcome, assessing the 
relationship with putative prognostic factors at baseline.  In this case, a general linear model with 
a Normal error term was used.    
For both analyses, initially univariable models were used, containing one putative prognostic 
variable alone. Then, a ‘full model’ was constructed containing all putative prognostic variables. A 
backwards deletion approach was then applied to reduce the model to include statistically 
significant explanatory variables only. This involved removing one variable at a time, the least 
statistically significant, until only statistically significant (set at the 5% level) variables remained in 
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the model.  This was termed the ‘final model’.   The univariate, full and final models are all 
reported.  Complete-case analysis was used and no imputation for missing data was applied.  
 
Sample size 
There is no consensus on the approach to compute power and sample size for logistic regression.  
However, to provide a target sample size we followed the approach of Demidenko30.  Assuming a 
binary explanatory variable with equal subjects in each category, and a 33 % probability of 
successful outcome, 535 observations within the model would provide 90% Power to detect a 
significant association at the 5% level with an odds ratio of 1.79; assuming a probability of success 
of 80%, the same statistical power would be conferred with around the same number for an odds 
ratio of 2.3. Not all individuals would have an intervention during the follow-up period (and 
therefore not be included in the modelling), though it was assumed the majority would. Allowing 
for up to 20% loss to follow-up a minimum target sample of 642 recruited was aimed for. 
Data management and data quality 
A bespoke database was built using MS SQL Server and a bespoke website and associated 
software was built using MS ASP.NET. Both were hosted by the Norwich Clinical Trials Unit secure 
server at the University of East Anglia. Patients who opted to complete their questionnaires online 
were sent a password protected email link inviting them to complete their next questionnaire. For 
those patients who chose to complete paper copies returned via business reply mail all data were 
entered by research associates.  Online submission of a questionnaire was only possible once all 
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mandatory fields were completed. Those returning incomplete paper questionnaires were 
contacted by the researchers to obtain any missing data where possible.   
For data entered into the database from paper copies a random sample of 100 completed baseline 
questionnaires were checked. The error rate was less than 0.3% (29 errors in 11000 fields) and 
therefore data quality was considered to be high.  
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Results 
A total of 1918 patients were invited to participate in the study, of whom 754 gave consent, met 
all eligibility criteria and returned full baseline questionnaires (see STROBE diagram Figure 1).  A 
total of 626 patients completed follow-up to 18 months (83%) and were included in the primary 
analysis. Their mean age was 61.5 (SD=12.4) years and 404 (65%) were women. The right hand 
was the worst hand in 409 (65%) cases and 422 (67%) reported bilateral CTS. The median duration 
of symptoms was 12 to 18 months and mean symptom severity was 3.0 (SD=0.8) points on CTS-6. 
The median disease severity by NCS grade for the worst hand was 3 (range 1 to 6). 
Of those participating, 318 (51%) underwent surgery for CTS in their worst hand within the first 6 
months post study entry, whilst 56 (9%) had a steroid injection only and 252 (40%) underwent no 
treatment. By 18 months, 403 (64%) had their worst hand treated surgically.  Repeated surgery 
was reported by 3 cases (<1%). A second injection in their worst hand was reported by 21 patients 
with 3 cases also receiving a third injection. By 18 months 165 patients (26%) remained untreated 
for their worst hand. 
Verification against the patients’ primary care records in a random sample of 84 participants (13%) 
showed that patient-report and primary care records for treatments by steroid and/or surgery 
concurred in 92% of cases (77 of the 84 surveyed). Steroid injections prior to surgical release and 
repeated injections were the most common discrepancies between the primary care record and 
the patient’s report, however only in 2 cases would this have led to a misclassification of 
treatment group.   
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Analyses of surgery outcome 
A global rating of change (GROC) at the first follow-up post-surgery was available for 455 surgical 
procedures over the full 18 months follow-up. These 455 were included in the GEE analysis. Of 
these, a successful outcome (using GROC≥3) was reported in 412 (91%) and 43 (9%) had a negative 
outcome (unchanged or worse). A comparison between those reporting a positive or negative 
outcome is presented in Table 1. Higher health utility derived from EQ5D-3L was the only 
consistent statistically significant prognostic factor for a positive outcome from surgery in the 
univariable, full and final model (Table 2).  Lower anxiety and depression scores (HADS) were 
significantly associated with GROC but only in the univariable analysis and did not remain in the 
full or final model. A sensitivity analysis  based on a more stringent cut-off for success (GROC 4 & 5 
only) identified 353 procedures (78%)  as having a positive outcome from surgery. Lower 
comorbidity score and lower anxiety were the only consistently significant predictors  for outcome 
in the univariable and final model (comorbidity OR=0.93. 95% CI: 0.89 to 0.98, p= 0.011; HADS 
Anxiety OR=0.94, 95%CI: 0.89 to 0.99). p=0.11) (Supplementary Table 1). 
The second analysis was based upon 406 surgically treated patients with symptom severity (CTS-6) 
available at 18 months. The explanatory variables were all recorded at baseline. These general 
linear models identified 3 baseline variables  associated with lower symptom severity at 18 
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months which were statistically significant in both the full and final models: lower comorbidity  
score (β=0.03, 95%CI: 0.02 to 0.04, p<0.001), lower CTS-6 score at baseline (β= 0.11, 95%CI: 0.03 
to 0.18, p=0.007), and lower anxiety (β= -0.02, 95%CI: 0.01 to 0.04, p<0.001) (Supplementary Table 
2). For the final model, the R2 was 12.0% and the adjusted R2 was 11.3%. 
 
 
Analyses of steroid injection outcome 
The dichotomised outcome from 150 GROCs post-steroid injections were available for analyses.  
Table 3 gives the clinical and demographic details by outcome, either positive or negative. A 
shorter duration of symptoms and not having had a previous steroid injection were consistent 
statistically significant predictors of a positive outcome (Table 4).   
Using CTS-6 at 18 months as outcome, a general linear model was constructed with the same 
baseline explanatory variables, as in the surgical model. Lower baseline CTS-6 score (β=0.55, 
95%CI: 0.33 to 0.77, p<0.001) was the only consistent statistically significant predictor of better 
symptom score in the full and final models (Supplementary Table III). For the final model R2 was 
22.9% and adjusted R2 was 21.3%. 
A summary of predictive factors by outcome model and intervention is given in table 5. 
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Discussion 
Our multivariable models included a total of 18 variables.  Of these 4 were found to be 
consistently associated with patient perceived improvement or lower symptom scores (CTS-6) 
after surgery:  a higher health-related quality of life index (EQ-5D utility), a lower comorbidity 
score, lower symptom-severity score and lower anxiety score.  In patients treated by steroid 
injections, 3 prognostic variables were consistently associated with a positive outcome or lower 
symptom score at 18 months: shorter duration of symptoms, not having had a prior steroid 
injection and lower symptom score at baseline.  It is likely that some of the predictor variables are 
related and hence there is potential for collinearity, for example the EQ-5D and comorbidity score, 
as observed in the models of surgery outcome when using two different cut-offs for GROC . This 
may also explain why some variables were statistically significant in the univariable model but not 
in the full or final model.  
The two different outcome measures, the dichotomised GROC and CTS-6, gave rise to differing 
sets of models and identified associations. This is perhaps not surprising.  The GROC models were 
based upon data over a relatively short time period, 6 months, whilst the CTS-6 models covered an 
18 month period and there is no reason why prognostic factors would be the same over differing 
time spans.  Further, the GROC outcome required a comparative reporting by the patients; in 
contrast the CTS-6 modelling was based upon symptoms reported at 18 months without reference 
to any previous time point.   
Our findings concur in part with previous studies, however direct comparison is not possible due 
to the wide variation in explanatory variables included and the way outcome was modelled.   
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Two very recently published studies have examined predictors of outcome from surgery for CTS 31 
32. Jansen et al31 modelled outcome using the Boston Carpal Tunnel Questionnaire (BCTQ) at 6 
months post-surgical decompression in 1,049 patients and found pre-surgical BCTQ score and 
presence of other hand comorbidities to be the strongest predictors of outcome. In contrast to our 
findings, it was a lower BCTQ score which predicted poorer outcome and those with more severe 
symptoms at intake showed the greatest change in BCTQ score.  Measures of psychological status, 
health-related quality of life and comorbid health conditions were not included. Moreover, they 
modelled outcome using change in BCTQ score over 6 months only which may explain why their 
findings differ from ours.  
A study by Bowman et al32 based on 3332 surgically treated patients applied  both logistic 
regression and artificial neural network analysis on a total of 87 candidate variables, although 
several pertained to individual questions within  the same questionnaire, increasing the risk of 
overfitting from collinearity in the regression model 32. Both the derivation cohort and subsequent 
validation cohort identified that those with moderately severe nerve conduction abnormalities, 
female gender, nocturnal waking, family history of CTS and a good response to corticosteroid 
injection were predictors for surgical success. Outcome was modelled using the same global rating 
of change as our study, although Bowman et al used ‘much better’ or ‘cured’ as criteria for 
success.  Conversely, greater functional impairment, presence of diabetes and hypertension and 
having surgery on the dominant hand were associated with poorer outcome. We did not find 
diabetes was an independent predictor however, overall  lower comorbidity score was when using 
the same GROC cut-off for classifying success as Bowman et al32.   
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Fewer studies have examined prognostic factors for steroid injection. Evers et al17 considered only 
a limited range of prognostic factors for treatment failure after initial steroid injection and also did 
not include psychological status, health-related quality of life or comorbidity. Patients were 
followed up over a median of 7.4 years. Re-intervention (i.e. treatment failure) was reported in 
67%  of 595 patients. Lower disease severity (from nerve electrodiagnostic tests) and higher 
injectate volume were associated with lower likelihood of failure. The authors acknowledge the 
limitations of using re-intervention as an outcome.  
Our finding that higher baseline health utility predicts a successful outcome after surgery  concurs 
with Rege et al 33 who report poorer pre-operative health status, assessed by the Nottingham 
Health Profile, was associated with lower satisfaction after surgery at 4 months.  Similarly, we 
found comorbidity score to be an independent predictor for surgical outcome when assessed by 
symptom score at 18 months. Our study included a comprehensive measure of comorbidity, the 
SACQ28, which not only encompasses the number of self-reported comorbidities but also weights 
each according to whether it requires treatment and limits activities.  
The finding that lower anxiety was an independent predictor for better surgical outcome in CTS is 
consistent with existing low quality evidence from the CTS literature15.  
The generalisability of our findings is high. The sociodemographic and clinical characteristics of the 
study sample were representative of the population and compares well with regards to age, male 
to female ratio with  that of Bowman et al’s large sample drawn from the Canterbury carpal tunnel 
clinic32.    
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There are some limitations. Except for NCS, all data were patient-reported, which made it easy to 
collect by mail or online, but is subject to bias from misreporting.  A disadvantage of using global 
rating of change is the potential for recall bias 34.  On the other hand they are quick, easy to 
complete and have been shown to have high test-retest reliability (ICC=0.9) and strong 
correlations with other measures of health status indicating construct validity 35 .   In this study 
patients had to estimate relative change over a 6 months period and for each hand separately. 
Therefore outcome models were also constructed using a symptom status measure (CTS-6) as an 
additional patient-reported outcome,  which captures symptoms at the actual point of follow-up, 
without any risk of recall bias.  Patients were obviously not blind to the treatments received. This 
may have influenced their scoring of symptoms, function and overall outcome. Patients’ beliefs, 
expectations from different treatments may have heightened their vigilance to symptoms and 
affected treatment seeking behaviours, though the fact that data were not collected by the 
treating clinicians may have mitigated against any social desirability effects in their responses.   
The classification of those treated by steroid injection who subsequently have surgery as a 
negative response to injection may be disputed as injections are often used to provide short-term 
relief where surgery may be delayed due to waiting lists. However the additional effect of surgery 
is likely to result in a greater perceived change (when using GROC) and lower symptoms (when 
using CTS-6) and would lead to a bias in models of outcome from steroid injection. 
 
Despite local clinical commissioning policies14 which advocate conservative treatment first, the 
proportion of participants having a steroid injection in the first 6 months was only 9% and in 
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contrast to 52% proceeding directly to surgery. This may be due, in part, to some patients having 
had symptoms for some time or receiving a steroid injection prior to referral for NCS and 
enrolment in our study. However, whilst three quarters of the surgically treated patients reported 
a symptom duration greater than 6 months, only 19% reported having had a prior injection. A 
more likely explanation is that these patients did not seek treatment until their symptoms were 
severe or functionally limiting, thus making them eligible for direct referral to surgery under local 
polices.  
 
Conclusions 
This large prospective cohort study has identified several independent predictor variables for 
outcome from surgery and steroid injection for CTS not previously studied. Higher health utility, 
fewer comorbidities, being less anxious and a lower symptom severity at the outset were 
independent significant predictors for better outcome from surgery. In patients treated by steroid 
injection a shorter duration of symptoms, not having had a prior injection and a lower symptom 
severity at the outset were significant independent predictors for better outcome.   
Our study is an important first step in developing prognostic models which, subject to further 
external validation, could be used to stratify care for CTS.  The routine inclusion of patient-
reported measures of health-related quality of life, psychological status and comorbidity alongside 
disease-specific symptom scores could help inform shared decision-making about best treatment 
and likely prognosis. 
 
 
This article is protected by copyright. All rights reserved.
 
 
 
Tables: 
 
Table 1: Clinical and sociodemographic characteristics of surgically treated grouped by Global 
Rating ofChange (slightly improved, much better and cured=success) 
Table 2: Generalised Estimation Equation (GEE) Modelling of Global Rating of Change Outcome 
from surgery (n=445) 
Table 3: Clinical and sociodemographic characteristics of patients treated by injection grouped by 
GROC 
Table 4: Generalised Estimation Equation (GEE) Modelling of Global Rating of Change Steroid 
Injection Outcome (n=150 injections) 
Table 5: Summary of independent factors predicting a better outcome from surgery and steroid 
injection 
 
Figures 
Figure 1: STROBE flowchart 
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Table 1: Generalised Estimation Equation Modelling of Positive Global Rating of Change Outcome 
(GROC≥4) from surgery (n=445 procedures) 
Table 2: General Linear Modelling of symptom severity outcome from surgery at 18 months 
(n=406) 
Table 3: General Linear Modelling of symptom severity outcome from steroid injection at 18 
months (n=102 patients treated with injection) 
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Table 1: Clinical and sociodemographic characteristics of surgically treated grouped by Global 
Rating of Change  
variables Score range Failure 
 (N=43) 
Success 
(N=412) 
Age yrs  62.2  (12.9) 62.3  (12.2) 
Body mass index  27.6  (  4.9) 28.6  (  5.5) 
Drink (Units)    5.1  (11.8)   4.7  (  6.8) 
Comorbidity Score  (0 to 36)   5.5  (  4.1)   5.2  (  4.1) 
EQ-5D-3L Utility (0 to 1)   0.56  (0.30)   0.65 (0.26) 
MHQ Total Score (0 to 100) 54.0  (25.7) 59.7  (22.3) 
CTS-6 (1 to 5)   3.1  (  0.9)   3.1  (  0.8) 
HADS – Anxiety (0-21)   7.5  (  5.0)   5.9  (  4.3) 
HADS – Depression (0 to21)   6.0  (  4.8)   4.4  (  3.9) 
NCS Grade  (1 to 6)   3.6  (  1.5)   3.7  (  1.3) 
Sex Male   30  (70%) 263  (64%) 
 Female   13  (30%) 149  (36%) 
    
Work Status Working   21  (49%) 184  (45%) 
 Non-working   22  (51%) 228  (55%) 
    
Smoking Status Non-smoker   21  (49%) 217  (53%) 
 Ex-Smoker   15  (35%) 161  (39%) 
 Current Smoker     7  (16%)   33  (  8%) 
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Has Diabetes Yes     5  (12%)   49  (12%) 
 No   38  (88%) 363  (88%) 
Variables cont’d Score range Failure (N=43) Success (N=412) 
Income category £15-21.5K     4  (  9%)   59  (14%) 
 £21.5-34.9K     8  (19%)   88  (21%) 
 £35-50K     3  (  7%)   43  (10%) 
 >£50K     2  (  5%)   21  (  5%) 
 Rather not say   18  (42%) 107  (26%) 
    
Bilateral Disease Yes   31  (72%) 284  (69%) 
 No   12  (28%) 128  (31%) 
    
Duration Category <3 months   3  (  7%)   21  (  5%) 
 3-6 months   6  (14%)   67  (16%) 
 6-12 months   8  (19%) 102  (25%) 
 12-18 months   6  (14%)   56  (14%) 
 >18 months 20  (47%) 166  (40%) 
    
Prior Injection Yes – Helped     3  (  7%)   55  (13%) 
 Yes – Unhelpful     3  (  7%)   25  (  6%) 
 No   37  (86%) 332  (81%) 
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Values reported as mean (standard deviation) or numbers (percentage) 
Legend:  MHQ- Michigan Hand Questionnaire; CTS-6 shortened Boston Questionnaire; HADS – 
Hospital Anxiety and Depression Scale ; NCS – Nerve conduction Studies
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Table 2: Generalised Estimation Equation (GEE) Modelling of Global Rating of Change (success ≥3) Outcome from surgery (n=445)  
  Univariate  Full Model  Final Model  
Variables  O.R. (95% C.I.) p-value O.R. (95% C.I.) p-value O.R. (95% C.I.) p-value 
Age  1.00  (0.98, 1.03) 0.935 0.97 (0.93, 1.02) 0.259   
Body Mass Index  1.04  (0.98, 1.11) 0.227 1.05  (0.96, 1.14) 0.284   
Drink (Units)  0.99  (0.94, 1.05) 0.762 1.08  (0.98, 1.19) 0.138   
Comorbidity Score  0.98  (0.91, 1.06) 0.638 0.98  (0.87, 1.10) 0.742   
EQ-5D-3L Utility  3.17  (1.22, 8.26) 0.018 2.14  (0.24, 19.19) 0.498 3.17 (1.22, 8.26) 0.018 
MHQ Total Score  1.01 (0.99, 1.03) 0.144 0.99 (0.96, 1.01) 0.359   
CTS-6  1.00  (0.65, 1.55) 0.984 0.97  (0.48, 2.09) 0.931   
HADS – Anxiety  0.93  (0.87, 0.99) 0.023 1.02  (0.90, 1.16) 0.710   
HADS – Depression  0.92  (0.85, 0.98) 0.015 0.92  (0.77, 1.09) 0.317   
NCS Grade  1.05  (0.82, 1.35) 0.728 1.21  (0.86, 1.69) 0.268   
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Income  0.87  (0.72, 1.04) 0.113 0.85  (0.53, 1.35) 0.480   
Duration  0.93  (0.71, 1.22) 0.600 0.89  (0.62, 1.29) 0.547   
Sex Male 0  0    
 Female 1.30  (0.66, 2.58) 0.455 1.30 (0.52, 3.30) 0.575   
  Univariate  Full Model  Final Model  
  O.R. (95% C.I.) p-value O.R. (95% C.I.) p-value O.R. (95% C.I.) p-value 
Smoking Status Smoker 0  0    
 Ex-Smoker 2.28 (0.85, 6.14) 0.104 2.00  (0.40, 9.96) 0.398   
 Non-Smoker 2.19  (0.86, 5.58) 0.100 1.38  (0.28, 6.87) 0.691   
Diabetic No 0  0    
 Yes 0.97 (0.36, 2.56) 0.955 0.97  (0.39, 2.42) 0.753   
Bilateral Disease No 0  0    
 Yes 1.17  (0.56, 2.43) 0.677 0.94  (0.42, 2.08) 0.956   
Prior Injection No 0  0    
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 Yes-Helped 2.05  (0.61, 6.90) 0.247 2.00  (0.38, 10.58) 0.415   
 Yes-Unhelpful 0.93  (0.27, 3.24) 0.911 0.82  (0.15, 4.41) 0.815   
Legend:  MHQ- Michigan Hand Questionnaire; CTS-6 shortened Boston Questionnaire; HADS – Hospital Anxiety and Depression Scale ; NCS – Nerve 
conduction Studies 
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Table 3: Clinical and sociodemographic characteristics of patients treated by injection grouped 
by Global Rating of Change 
Variables Score range Failure (N=86) Success  (N=64) 
Age  60.8  (12.2) 61.0  (11.3) 
Body Mass Index  28.8  (  5.9) 29.3  (  8.3) 
Drink (Units)    3.6  (  5.6)   5.3  (  6.3) 
Comorbidity Score (0 to 36)   5.1  (  3.6)   5.9  (  4.3) 
EQ-5D-3L Utility (0 to 1)   0.61  (0.31)   0.69  (0.25) 
MHQ Total Score (0 to 100) 63.7  (23.0) 66.9  (21.1) 
CTS6 (1 to 5)   2.7  (  0.86)   2.7  (  0.85) 
HADS – Anxiety (0-21)   6.5  (  5.0)   6.9  (  4.7) 
HADS – Depression (0 to21)   4.4  (  3.9)   4.8  ( 3.7) 
NCS Grade (1 to 6)   2.7  (  1.4)   2.5  (  1.3) 
    
Sex Male   59  (69%)   45  (70%) 
 Female   27  (31%)   19  (30%) 
    
Work Status Working   38  (44%)   33  (52%) 
 Non-working   48  (56%)   31  (48%) 
    
Smoking Status Non-smoker   46  (53%)   35  (55%) 
 Ex-Smoker   31  (36%)   21  (33%) 
 Current Smoker     9  (10%)     8  (13%) 
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Has Diabetes Yes     6  (  7%)     8  (13%) 
 No   80  (93%)   56  (87%) 
    
Variables (cont’d  Failure (n=86) Success (n=64) 
Income Category <£15K   19  (22%)   14  (22%) 
 £15-21.5K   11  (13%)   14  (22%) 
 £21.5-34.9K   17  (20%)   17  (27%) 
 £35-50K     4  (  5%)     4  (  6%) 
 >£50K     8  (  9%)     2  (  3%) 
 Rather not say   27  (31%)   13  (20%) 
Bilateral Disease Yes   54  (63%)   45  (70%) 
 No   32  (37%)   19  (30%) 
Duration Category <3 months     1  (  1%)     3  (  5%) 
 3-6 months   15  (17%)   25  (39%) 
 6-12 months   23  (27%)   13  (20%) 
 12-18 months   13  (15%)     5  (  8%) 
 >18 months   34  (40%)   18  (35%) 
Prior Injection Yes – Helped   25  (29%)     6  (  9%) 
 Yes – Unhelpful     4  (  5%)     0   
 No   57  (66%)   58  (91%) 
 
Values reported as mean (standard deviation) or numbers (percentage) 
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Legend:  MHQ- Michigan Hand Questionnaire; CTS-6 shortened Boston Questionnaire; HADS – 
Hospital Anxiety and Depression Scale ; NCS – Nerve conduction Studies 
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Table 4: Generalised Estimation Equation (GEE) Modelling of Global Rating of Change outcome for Steroid Injection (n=150 injections) 
  Univariate  Full Model  Final Model  
Variables  O.R. (95% C.I.) p-value O.R. (95% C.I.) p-value O.R. (95% C.I.) p-value 
Age  1.00 (0.98, 1.03) 0.922 0.99 (0.94, 1.04) 0.654   
Body Mass Index  1.01 (0.97, 1.05) 0.596 1.03 (0.94, 1.14) 0.510   
Drink (Units)  1.05 (1.00, 1.11) 0.074 1.12 (1.01, 1.23) 0.026 1.07 (1.00, 1.15) 0.037 
Comorbidity Score  1.06 (0.98, 1.14) 0.148 1.07 (0.96, 1.21) 0.220 1.13 (1.03, 1.25) 0.012 
EQ-5D Utility  2.90 (0.90, 9.34) 0.075 14.5 (0.92, 226.5) 0.057 5.20 (1.16, 23.4) 0.037 
MHQ Total Score  1.01 (0.99, 1.02) 0.375 1.01 (0.96, 1.06) 0.721   
CTS6  1.03 (0.70, 1.53) 0.872 1.37 (0.58, 3.26) 0.475   
HADS – Anxiety  1.02 (0.95, 1.09) 0.630 0.92 (0.76, 1.11) 0.366   
HADS – Depression  1.03 (0.94, 1.13) 0.536 1.19 (0.94, 1.51) 0.150   
NCS Grade  0.92 (0.72, 1.18) 0.516 0.90 (0.63, 1.28) 0.554   
Income  0.86 (0.73, 1.02) 0.089 0.90 (0.59, 1.36) 0.609   
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Duration  0.69 (0.53, 0.90) 0.007 0.65 (0.42, 0.99) 0.044 0.73 (0.54, 0.98) 0.036 
Sex Male 1.00  1.00    
 Female 0.92 (0.47, 1.81) 0.815 0.69 (0.24, 1.97) 0.484   
  Univariate  Full Model  Final Model  
  O.R. (95% C.I.) p-value O.R. (95% C.I.) p-value O.R. (95% C.I.) p-value 
Work Status Non-working 1.00  1.00  1.00  
 Working 0.74 (0.39, 1.43) 0.373 1.93 (0.65, 5.75) 0.237 2.20 (1.05, 4.60) 0.037 
Smoking Status Smoker 1.00  1.00    
 Ex-Smoker 0.76 (0.22, 2.63) 0.668 0.58 (0.09, 3.35) 0.523   
 Non-Smoker 0.86 (0.26, 2.77) 0.795 0.59 (0.10, 3.43) 0.559   
Has Diabetes No 1.00  1.00    
 Yes 1.90 (0.70, 5.18) 0.207 2.03 (0.09, 48.5) 0.661   
Bilateral Disease No 1.00  1.00    
 Yes 1.41 (0.71, 3.03) 0.323 2.52 (0.97, 6.59) 0.059   
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Prior Injection No 1.00  1.00  1.00  
 Yes 0.20 (0.08, 0.50) <0.001 0.77 (0.19, 3.07) 0.003 0.18 (0.07, 0.47) <0.001 
Legend:  MHQ- Michigan Hand Questionnaire; CTS-6 shortened Boston Questionnaire; HADS – Hospital Anxiety and Depression Scale ; NCS – Nerve 
conduction Studies 
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Table 5: Summary of independent factors predicting a better outcome from surgery and steroid injection 
 Surgery Steroid injection 
   
GROC ≥3 (slightly 
better) 
Higher EQ5D health utility 
(Lower HADS Anxiety and Depression) 
Shorter duration of symptoms 
No previous steroid injection 
   
GROC ≥4 (much 
improved) 
Lower Comorbidity score 
Lower HADS Anxiety 
N/A 
   
Lower symptom 
severity (CTS-6) at 18 
months 
Lower Comorbidity score 
Lower symptom score at baseline 
Lower HADS anxiety score 
Lower symptom score at baseline 
 
 
 
This article is protected by copyright. All rights reserved.
 
 
Legend: GROC- global rating of outcome; CTS-6 shortened Boston Carpal Tunnel Questionnaire, HADS – Hospital Anxiety and Depression Scale;    
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Abbreviations used:  
CI – confidence interval 
CTS-6 – 6 item carpal tunnel syndrome questionnaire 
CTS -  carpal tunnel syndrome  
EQ5D – EuroQuol 5 dimensions 
GROC – global rating of change 
HADS – Hospital Anxiety and Depression Scale  
NCS – nerve conduction studies 
OR – odds ratio 
p - probability    
SACQ – Self-assessed comorbidity Questionnaire  
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